Figure 1. Responses to treatment before
haploidentical-BMT. Shown are PET-CT images performed after each
respective treatment (Post-Rx). Post-Dx mo. indicate months after
initial diagnosis. (A) extension of disease below the diaphragm
following dose adjusted etoposide, prednisone, vincristine,
cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) and involved
field irradiation; (B) interim response after receiving ifosfamide,
carboplatin, etoposide and rituximab (ICE-R), then navelbine and
doxorubicin (R-GND) followed by first dose of pembrolizumab; (C)
progression of disease after eight doses of pembrolizumab; (D) partial
response after brentuximab vedotin; (E) failure to respond to anti-CD19
CAR-T cell therapy; (F) very good partial response after bendamustine
and brentuximab followed by gemcitabine, cisplatin and dexamethasone
(GCD).